WO2023042123 - ANTI-CGRP ANTIBODY DOSING AND SCREENING METHODS
National phase entry is expected:
Publication Number
WO/2023/042123
Publication Date
23.03.2023
International Application No.
PCT/IB2022/058723
International Filing Date
15.09.2022
Title **
[English]
ANTI-CGRP ANTIBODY DOSING AND SCREENING METHODS
[French]
PROCÉDÉS DE DOSAGE ET DE CRIBLAGE D'ANTICORPS ANTI-CGRP
Applicants **
H. LUNDBECK A/S
Ottiliavej 9
2500 VALBY, DK
Inventors
CADY, Roger, K.
Ottiliavej 9
2500 Valby, DK
ANDERSON, Carlton
Ottiliavej 9
2500 Valby, DK
BRUNNER, Elizabeth
Ottiliavej 9
2500 Valby, DK
HIRMAN, Joseph
Ottiliavej 9
2500 Valby, DK
Priority Data
63/244,466
15.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1247 | |
| EPO | Filing, Examination | 6159 | |
| Japan | Filing | 597 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 11288 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates the use of monoclonal anti-calcitonin gene-related peptide (CORP) antagonist antibodies or anti-CGRP receptor antibodies in subjects that do not respond adequately to a first dose but respond to the second dose.[French]
La présente invention concerne l'utilisation d'anticorps antagonistes monoclonaux dirigés contre le peptide apparenté au gène calcitonine (CORP) ou des anticorps dirigés contre le récepteur CGRP chez des sujets qui ne répondent pas de manière adéquate à une première dose mais qui répondent à la seconde dose.